(Q51725634)

10 April 2018

editorial

0 references

title

Translational research in oncolytic measles virotherapy: early discoveries and future steps. (English)

1 reference

10 April 2018

1 reference

1 reference

3

Evanthia Galanis

1 reference

10 April 2018

author name string

Pavlos Msaouel

series ordinal

1

1 reference

10 April 2018

Mateusz Opyrchal

series ordinal

2

1 reference

10 April 2018

publication date

1 February 2011

1 reference

10 April 2018

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

10 April 2018

volume

6

1 reference

10 April 2018

issue

2

1 reference

10 April 2018

page(s)

125-128

1 reference

10 April 2018

The origins and ongoing evolution of viruses

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

SLAM (CDw150) is a cellular receptor for measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Measles virus as an oncolytic vector platform

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Interaction of measles virus vectors with Auger electron emitting radioisotopes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Engineering oncolytic measles virus to circumvent the intracellular innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.170

21 January 2018

Identifiers

DOI

10.2217/FMB.10.170

1 reference

10 April 2018

1 reference

10 April 2018